Latest Insider Transactions at Pacira Bio Sciences, Inc. (PCRX)
This section provides a real-time view of insider transactions for Pacira Bio Sciences, Inc. (PCRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Pacira BioSciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Pacira BioSciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2021
|
John P Phd Longenecker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+18.01%
|
$65,000
$13.98 P/Share
|
|
Feb 03
2021
|
David M Stack CEO and Chairman |
SELL
Open market or private sale
|
Direct |
21,250
-11.48%
|
$1,508,750
$71.1 P/Share
|
|
Feb 03
2021
|
David M Stack CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+17.92%
|
$212,500
$10.81 P/Share
|
|
Feb 02
2021
|
David M Stack CEO and Chairman |
SELL
Open market or private sale
|
Direct |
21,250
-7.73%
|
$1,466,250
$69.33 P/Share
|
|
Feb 02
2021
|
David M Stack CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
21,250
+17.92%
|
$212,500
$10.81 P/Share
|
|
Jan 06
2021
|
Max Reinhardt President, Rest of World |
SELL
Open market or private sale
|
Direct |
110
-0.78%
|
$6,600
$60.81 P/Share
|
|
Nov 16
2020
|
Laura Brege Director |
SELL
Open market or private sale
|
Direct |
12,000
-60.24%
|
$780,000
$65.95 P/Share
|
|
Nov 16
2020
|
Laura Brege Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+37.59%
|
$156,000
$13.98 P/Share
|
|
Nov 13
2020
|
Max Reinhardt President, Rest of World |
SELL
Open market or private sale
|
Direct |
25,000
-35.13%
|
$1,575,000
$63.09 P/Share
|
|
Nov 13
2020
|
Max Reinhardt President, Rest of World |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+39.06%
|
$1,050,000
$42.54 P/Share
|
|
Nov 13
2020
|
Roy Winston Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-12.57%
|
$310,000
$62.0 P/Share
|
|
Nov 13
2020
|
Lauren Bullaro Riker Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
3,000
-18.54%
|
$189,000
$63.81 P/Share
|
|
Nov 13
2020
|
Lauren Bullaro Riker Senior Vice President, Finance |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+15.64%
|
$30,000
$10.81 P/Share
|
|
Oct 16
2020
|
David M Stack CEO and Chairman |
SELL
Open market or private sale
|
Direct |
30,000
-14.75%
|
$1,650,000
$55.56 P/Share
|
|
Oct 16
2020
|
David M Stack CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.85%
|
$300,000
$10.81 P/Share
|
|
Oct 15
2020
|
David M Stack CEO and Chairman |
SELL
Open market or private sale
|
Direct |
30,000
-14.75%
|
$1,650,000
$55.0 P/Share
|
|
Oct 15
2020
|
David M Stack CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.85%
|
$300,000
$10.81 P/Share
|
|
Oct 14
2020
|
David M Stack CEO and Chairman |
SELL
Open market or private sale
|
Direct |
30,000
-14.75%
|
$1,650,000
$55.53 P/Share
|
|
Oct 14
2020
|
David M Stack CEO and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+12.85%
|
$300,000
$10.81 P/Share
|